Aegerion Pharmaceuticals Earnings: Here’s Why Investors are Happy Now

Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) had a loss and missed Wall Street’s expectations, BUT beat the revenue expectation. The revenue beat is a positive sign to shareholders seeking high growth out of the company. Shares are up 9.32%.

Aegerion Pharmaceuticals, Inc. Earnings Cheat Sheet

Results: Adjusted Earnings Per Share decreased to $-0.66 in the quarter versus EPS of $-0.63 in the year-earlier quarter.

Revenue: Was the same at $6.5 million as the year-earlier quarter.

Actual vs. Wall St. Expectations: Aegerion Pharmaceuticals, Inc. reported adjusted EPS loss of $0.66 per share. By that measure, the company missed the mean analyst estimate of $-0.62. It beat the average revenue estimate of $4.27 million.

Quoting Management: “We continue to execute on launch, advancing early market uptake, and we see significant room for continued growth as we calibrate our activities surrounding the launch of JUXTAPID in the U.S.,” said Marc D. Beer, Chief Executive Officer. “Most importantly, we’re positively impacting HoFH patients in need of treatment. With six months of commercial experience, we have a greater sense of the significant need that exists for HoFH patients globally, and that understanding reinforces our confidence in the market potential.”

Key Stats (on next page)…

Revenue increased 428.46% from $1.23 million in the previous quarter. EPS decreased to $-0.66 in the quarter versus EPS of $-0.64 in the previous quarter.

Looking Forward: Analysts have a more positive outlook for the company’s next-quarter performance. Over the past three months, the average estimate for next quarter’s earnings has risen from a loss of $0.59 to a loss $0.52. For the current year, the average estimate has moved up from a loss of $2.38 to a loss of $2.22 over the last ninety days.

Stocks with improving earnings metrics are worthy of your extra attention. In fact, “E = Earnings Are Increasing Quarter-Over-Quarter” is a core component of our CHEAT SHEET investing framework for this very reason. Don’t waste another minute – click here and get our CHEAT SHEET stock picks now.

(Company fundamentals provided by Xignite Financials. Email any earnings discrepancies to earnings [at]